Ozempic maker Novo Nordisk’s patent expires March 20: Generic semaglutide rush set to disrupt India’s weight-loss drug market
- Posted on March 20, 2026
- By Financial Express
- 7 Views
Ozempic maker Novo Nordisk’s patent expires March 20: Generic semaglutide rush set to disrupt India’s weight-loss drug market
Natco Pharma plans to launch a semaglutide injection, the key ingredient in Novo Nordisk’s Ozempic and Wegovy, at a starting price of Rs 1,290 per month as soon as generics are allowed, Bloomberg reported.
